Summary

Autoimmune Disease Diagnostics Market By Product (Consumables & Assay Kits, Instruments, Software & Services), By Test Type (Antinuclear Antibody Tests, Autoantibody Tests, C-Reactive Protein Tests, Erythrocyte Sedimentation Rate Tests, Complete Blood Count, Others), By Technology (ELISA, Radioimmunoassay, Immunofluorescence Assay, Multiplex Assays, Immuno), By Disease Type (Systemic Autoimmune Diseases {Rheumatoid Arthritis, Systemic Lupus Erythematosus, Sjogren’s Syndrome, Scleroderma}, Organ-Specific Autoimmune Diseases {Type 1 Diabetes, Hashimoto’s Thyroiditis, Graves’ Disease, Celiac Disease, Multiple Sclerosis, Others}), By End-user (Hospitals, Clinical Laboratories, Diagnostic Centers, Research Institutes).Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles, and Market Forecast, 2025 ? 2035
The Autoimmune Disease Diagnostics market accounted for USD 5.74 Billion in 2024 and is expected to reach USD 11.24 Billion by 2035, growing at a CAGR of around 6.30% between 2025 and 2035. This report gives an insight into the major diagnostic techniques used to diagnose autoimmune diseases such as rheumatoid arthritis, lupus, and multiple sclerosis. This market has grown over time due to the increasing incidence rate of autoimmune diseases, advanced technologies in diagnostic equipment, and the development of awareness of diseases and early diagnosis. The improved and faster diagnosis is a result of employing more sophisticated technologies, such as multiplex assays and AI-based platforms. The genomics market is further complemented by increasing healthcare spending, especially in the progressing territories and patient individualization. Owing to such developments and the increasing number of patients now, the autoimmune disease diagnostics market is predicted to develop further in the next few years.
Advancements in Diagnostic Technologies
Mostly, the market for diagnostic solutions has been buoyant because of continuous innovation and development of the latest technologies. In this respect, multiplex assays and biosensors have been successfully developed to detect autoimmune diseases. Diagnoses and treatment efficiency are improved, and time reduction in diagnostics is facilitated. This also adds more efficiency in workflow by connecting with the digital health tool. Laboratories are automated, and automation reduces human error and improves workflow. In the case of the medical professionals, this will provide them with this enhanced reliability and rapidity of the diagnosis.
Diagnostic Complexity and Misinterpretation
Symptoms of autoimmune diseases overlap, and this makes diagnosis difficult. An incorrect or delayed treatment may result from the misinterpretation of test results. This complicates efforts with the lack of specific biomarkers for certain conditions. This increases the diagnostic burden since clinicians must often rely on multiple tests. This specialty also has a shortage of specialists with experience in autoimmune pathology. The effect of these complexities is on the effectiveness and efficiency of the diagnostics.
Integration of AI and Data Analytics.
Through artificial intelligence, diagnosis of ailments is fast being done, and more accurate results are attained. There is a possibility of utilizing the AI platforms to find correlations of autoimmune diseases from large databases. This eliminates human discretion and helps in the early identification of bad credit risks. They are also used for tracking the development of diseases as well as signaling an early detection. It also aids in clinical decisions and treatment or patient care delivery. These have created new possibilities in the advancement of health care.
Segment Analysis
The test type include autoantibodies, inflammatory markers, and so on. Autoantibody tests identify bodies that an autoimmune system produces as an indication of autoimmune activity. Serologic tests determine the antibodies that lead to the disease outbreaks. These vary in their difficulty and the roles they play in analyzing and diagnosing a condition.
Some of the key end-users are the hospitals, diagnostic laboratories, and research centers. Diagnostics is usually applied as screening for inpatient and emergency cases in hospitals. This is because laboratories engage in special control procedures with a high degree of accuracy. In research centers, researchers spend effort and time on tests and the development of diagnostics.
Regional Analysis
North America is the most advanced in terms of diagnostics and healthcare facilities. The presence of major players increases the rate of new technology since there are increased technological advancements. Low awareness has contributed to high awareness levels among the people, hence widespread use of autoimmune disease testing. Furthering R & D investments keeps them in the competitive strategic position in this area.
Competitive Landscape
Competition is stiff within the market, given the high number of diagnostic companies in operation. There are usually strategic partnerships that top giants practice with the view to improve their product offerings. The established products and services can be modified to give them a competitive edge, an area in which firms have invested greatly in R&D. This is due to the reputation that is accorded a brand and, more so, the legalization that is given to new ideas. It is observed that many firms are applying AI and digital instruments in the diagnosis function. Competition by constant change and growth strategies is the main trend of the competitive environment.
Report Coverage:
By Product
- Consumables & Assay Kits
- Instruments
- Software & Services
By Test Type
- Antinuclear Antibody Tests
- Autoantibody Tests
- C-Reactive Protein (CRP) Tests
- Erythrocyte Sedimentation Rate (ESR) Tests
- Complete Blood Count (CBC)
- Others
By Technology
- ELISA (Enzyme-linked Immunosorbent Assay)
- Radioimmunoassay (RIA)
- Immunofluorescence Assay (IFA)
- Multiplex Assays
- Immuno
By Disease Type
- Systemic Autoimmune Diseases
- Rheumatoid Arthritis
- Systemic Lupus Erythematosus (SLE)
- Sjogren’s Syndrome
- Scleroderma
- Organ-Specific Autoimmune Diseases
- Type 1 Diabetes
- Hashimoto’s Thyroiditis
- Graves’ Disease
- Celiac Disease
- Multiple Sclerosis
- Others
By End-user
- Hospitals
- Clinical Laboratories
- Diagnostic Centers
- Research Institutes

ページTOPに戻る

Table of Contents

1. Methodology & Report Coverage
1.1. Definition & Objective
1.2. Market Evaluation & forecast parameter
1.3. Research Methodology
1.4. Data Validation Sources
1.4.1. Secondary Research
1.4.2. Primary Research
2. Market Overview
3. Autoimmune Disease Diagnostics Market: Market Dynamics
3.1. Executive Summary
3.2. Market Driving Factors
3.2.1. Increasing Prevalence of Autoimmune Diseases
3.2.2. Advancements in Diagnostic Technologies
3.2.3. Increasing Awareness and Healthcare Spending
3.3. Key Industry Pitfalls & Challenges
3.3.1. High Cost of Diagnostic Tests
3.3.2. Stringent Regulatory Requirements
3.3.3. Complexity of Autoimmune Diseases
3.4. Market Opportunities
3.4.1. Significant potential for growth in emerging markets
3.4.2. Advances in personalized medicine
3.4.3. Rising number of partnerships and collaborations
3.5. Porter’s Five Forces Analysis
3.6. PESTLE Analysis
3.7. Regulatory landscape
3.8. Pipeline Analysis
3.9. ESG Scenario
3.10. Competitive landscape
3.10.1. Company Market Share
3.10.2. Market Positioning
3.10.3. Strategy framework
3.10.4. Recent Acquisitions & Mergers
4. Autoimmune Disease Diagnostics Market, Product Type Segment Analysis
4.1. Overview Dynamics
4.1.1. Market Revenue Share, By Product Type, 2023 & 2034
4.1.2. Key Market Trends, Growth Factors, & Opportunities
4.2. Assay Kits and Reagents
4.2.1. ELISA (Enzyme-Linked Immunosorbent Assay) Kits
4.2.1.1. Market Revenue Share, By Product Type, 2023 & 2034
4.2.2. IFA (Immunofluorescence Assay) Kits
4.2.2.1. Market Revenue Share, By Product Type, 2023 & 2034
4.2.3. Multiplex Assays
4.2.3.1. Market Revenue Share, By Product Type, 2023 & 2034
4.3. Instruments
4.3.1. Analyzers
4.3.2. Readers
4.3.3. Software
4.4. Consumables
5. Autoimmune Disease Diagnostics Market, Disease Type Segment Analysis
5.1. Overview
5.1.1. Market Revenue Share, By Disease Type, 2023 & 2034
5.1.2. Key Market Trends, Growth Factors, & Opportunities
5.2. Rheumatoid Arthritis
5.2.1. Market Size and Forecast, By 2024-2034 (USD Million)
5.3. Systemic Lupus Erythematosus (SLE)
5.3.1. Market Size and Forecast, By 2024-2034 (USD Million)
5.4. Multiple Sclerosis
5.4.1. Market Size and Forecast, By 2024-2034 (USD Million)
5.5. Inflammatory Bowel Disease
5.5.1. Market Size and Forecast, By 2024-2034 (USD Million)
5.6. Type 1 Diabetes
5.6.1. Market Size and Forecast, By 2024-2034 (USD Million)
5.7. Psoriasis
5.7.1. Market Size and Forecast, By 2024-2034 (USD Million)
5.8. Others
5.8.1. Market Size and Forecast, By 2024-2034 (USD Million)
6. Autoimmune Disease Diagnostics Market, Test Type Segment Analysis
6.1. Overview
6.1.1. Market Revenue Share, By Test Type, 2023 & 2034
6.1.2. Key Market Trends, Growth Factors, & Opportunities
6.2. Antibody Tests
6.2.1. Market Size and Forecast, By 2024-2034 (USD Million)
6.3. Inflammatory Markers
6.3.1. Market Size and Forecast, By 2024-2034 (USD Million)
6.4. Imaging Tests
6.4.1. Market Size and Forecast, By 2024-2034 (USD Million)
6.5. Tissue Biopsies
6.5.1. Market Size and Forecast, By 2024-2034 (USD Million)
6.6. Complete Blood Count (CBC)
6.6.1. Market Size and Forecast, By 2024-2034 (USD Million)
6.7. Protein Electrophoresis
6.7.1. Market Size and Forecast, By 2024-2034 (USD Million)
6.8. Others
6.8.1. Market Size and Forecast, By 2024-2034 (USD Million)
7. Autoimmune Disease Diagnostics Market, Region Segment Analysis
7.1. Overview
7.1.1. Global Market Revenue Share, By Region, 2023 & 2034
7.1.2. Global Market Revenue, By Region, 2024-2034 (USD Million)
7.2. North America
7.2.1. North America Market Revenue, By Country, 2024-2034 (USD Million)
7.2.2. North America Market Revenue, By Product Type, 2024-2034
7.2.3. North America Market Revenue, By Disease Type, 2024-2034
7.2.4. North America Market Revenue, By Test Type, 2024-2034
7.2.5. The U.S.
7.2.5.1. U.S. Market Revenue, By Product Type, 2024-2034
7.2.5.2. U.S. Market Revenue, By Disease Type, 2024-2034
7.2.5.3. U.S. Market Revenue, By Test Type, 2024-2034
7.2.6. Canada
7.2.6.1. Canada Market Revenue, By Product Type, 2024-2034
7.2.6.2. Canada Market Revenue, By Disease Type, 2024-2034
7.2.6.3. U.S. Market Revenue, By Test Type, 2024-2034
7.3. Europe
7.3.1. Europe Market Revenue, By Country, 2024-2034 (USD Million)
7.3.2. Europe Market Revenue, By Product Type, 2024-2034
7.3.3. Europe Market Revenue, By Disease Type, 2024-2034
7.3.4. Europe Market Revenue, By Test Type, 2024-2034
7.3.5. Germany
7.3.5.1. Germany Market Revenue, By Product Type, 2024-2034
7.3.5.2. Germany Market Revenue, By Disease Type, 2024-2034
7.3.5.3. Germany Market Revenue, By Test Type, 2024-2034
7.3.6. France
7.3.6.1. France Market Revenue, By Product Type, 2024-2034
7.3.6.2. France Market Revenue, By Disease Type, 2024-2034
7.3.6.3. France Market Revenue, By Test Type, 2024-2034
7.3.7. U.K.
7.3.7.1. U.K. Market Revenue, By Product Type, 2024-2034
7.3.7.2. U.K. Market Revenue, By Disease Type, 2024-2034
7.3.7.3. U.K. Market Revenue, By Test Type, 2024-2034
7.3.8. Italy
7.3.8.1. Italy Market Revenue, By Product Type, 2024-2034
7.3.8.2. Italy Market Revenue, By Disease Type, 2024-2034
7.3.8.3. Italy Market Revenue, By Test Type, 2024-2034
7.3.9. Spain
7.3.9.1. Spain Market Revenue, By Product Type, 2024-2034
7.3.9.2. Spain Market Revenue, By Disease Type, 2024-2034
7.3.9.3. Spain Market Revenue, By Test Type, 2024-2034
7.3.10. Rest of Europe
7.3.10.1. Rest of Europe Market Revenue, By Product Type, 2024-2034
7.3.10.2. Rest of Europe Market Revenue, By Disease Type, 2024-2034
7.3.10.3. Rest of Europe Market Revenue, By Test Type, 2024-2034
7.4. Asia Pacific
7.4.1. Asia Pacific Market Revenue, By Country, 2024-2034 (USD Million)
7.4.2. Asia Pacific Market Revenue, By Product Type, 2024-2034
7.4.3. Asia Pacific Market Revenue, By Disease Type, 2024-2034
7.4.4. Asia Pacific Market Revenue, By Test Type, 2024-2034
7.4.5. China
7.4.5.1. China Market Revenue, By Product Type, 2024-2034
7.4.5.2. China Market Revenue, By Disease Type, 2024-2034
7.4.5.3. China Market Revenue, By Test Type, 2024-2034
7.4.6. Japan
7.4.6.1. Japan Market Revenue, By Product Type, 2024-2034
7.4.6.2. Japan Market Revenue, By Disease Type, 2024-2034
7.4.6.3. Japan Market Revenue, By Test Type, 2024-2034
7.4.7. India
7.4.7.1. India Market Revenue, By Product Type, 2024-2034
7.4.7.2. India Market Revenue, By Disease Type, 2024-2034
7.4.7.3. India Market Revenue, By Test Type, 2024-2034
7.4.8. South Korea
7.4.8.1. South Korea Market Revenue, By Product Type, 2024-2034
7.4.8.2. South Korea Market Revenue, By Disease Type, 2024-2034
7.4.8.3. South Korea Market Revenue, By Test Type, 2024-2034
7.4.9. Singapore
7.4.9.1. Singapore Market Revenue, By Product Type, 2024-2034
7.4.9.2. Singapore Market Revenue, By Disease Type, 2024-2034
7.4.9.3. Singapore Market Revenue, By Test Type, 2024-2034
7.4.10. Rest of Asia Pacific
7.4.10.1. Rest of Asia Pacific Market Revenue, By Product Type, 2024-2034
7.4.10.2. Rest of Asia Pacific Market Revenue, By Disease Type, 2024-2034
7.4.10.3. Rest of Asia Pacific Market Revenue, By Test Type, 2024-2034
7.5. Latin America
7.5.1. Latin America Market Revenue, By Country, 2024-2034 (USD Million)
7.5.2. Latin America Market Revenue, By Product Type, 2024-2034
7.5.3. Latin America Market Revenue, By Disease Type, 2024-2034
7.5.4. Latin America Market Revenue, By Test Type, 2024-2034
7.5.5. Brazil
7.5.5.1. Brazil Market Revenue, By Product Type, 2024-2034
7.5.5.2. Brazil Market Revenue, By Disease Type, 2024-2034
7.5.5.3. Brazil Market Revenue, By Test Type, 2024-2034
7.5.6. Mexico
7.5.6.1. Mexico Market Revenue, By Product Type, 2024-2034
7.5.6.2. Mexico Market Revenue, By Disease Type, 2024-2034
7.5.6.3. Mexico Market Revenue, By Test Type, 2024-2034
7.5.7. Argentina
7.5.7.1. Argentina Market Revenue, By Product Type, 2024-2034
7.5.7.2. Argentina Market Revenue, By Disease Type, 2024-2034
7.5.7.3. Argentina Market Revenue, By Test Type, 2024-2034
7.5.8. Rest of Latin America
7.5.8.1. Rest of Latin America Market Revenue, By Product Type, 2024-2034
7.5.8.2. Rest of Latin America Market Revenue, By Disease Type, 2024-2034
7.5.8.3. Rest of Latin America Market Revenue, By Test Type, 2024-2034
7.6. MEA
7.6.1. MEA Market Revenue, By Country, 2024-2034 (USD Million)
7.6.2. MEA Market Revenue, By Product Type, 2023– 2034
7.6.3. MEA Market Revenue, By Disease Type, 2024-2034
7.6.4. MEA Market Revenue, By Test Type, 2024-2034
7.6.5. GCC
7.6.5.1. GCC Market Revenue, By Product Type, 2024-2034
7.6.5.2. GCC Market Revenue, By Disease Type, 2024-2034
7.6.5.3. GCC Market Revenue, By Test Type, 2024-2034
7.6.6. South Africa
7.6.6.1. South Africa Market Revenue, By Product Type, 2024-2034
7.6.6.2. South Africa Market Revenue, By Disease Type, 2024-2034
7.6.6.3. South Africa Market Revenue, By Test Type, 2024-2034
7.6.7. Rest of Middle-East and Africa
7.6.7.1. Rest of Middle-East and Africa Market Revenue, By Product Type, 2024-2034
7.6.7.2. Rest of Middle-East and Africa Market Revenue, By Disease Type, 2024-2034
7.6.7.3. Rest of Middle-East and Africa Market Revenue, By Test Type, 2024-2034
8. Company Profiles
8.1. Thermo Fisher Scientific
8.1.1. Business Overview
8.1.2. Financial Performance
8.1.3. Product/Service Offerings
8.1.4. Strategies & recent developments
8.1.5. SWOT Analysis
8.2. Siemens Healthineers
8.2.1. Business Overview
8.2.2. Financial Performance
8.2.3. Product/Service Offerings
8.2.4. Strategies & recent developments
8.2.5. SWOT Analysis
8.3. Bio-Rad Laboratories
8.3.1. Business Overview
8.3.2. Financial Performance
8.3.3. Product/Service Offerings
8.3.4. Strategies & recent developments
8.3.5. SWOT Analysis
8.4. Abbott Laboratories
8.4.1. Business Overview
8.4.2. Financial Performance
8.4.3. Product/Service Offerings
8.4.4. Strategies & recent developments
8.4.5. SWOT Analysis
8.5. Danaher Corporation
8.5.1. Business Overview
8.5.2. Financial Performance
8.5.3. Product/Service Offerings
8.5.4. Strategies & recent developments
8.5.5. SWOT Analysis
8.6. F. Hoffmann-La Roche Ltd
8.6.1. Business Overview
8.6.2. Financial Performance
8.6.3. Product/Service Offerings
8.6.4. Strategies & recent developments
8.6.5. SWOT Analysis
8.7. Grifols S.A.
8.7.1. Business Overview
8.7.2. Financial Performance
8.7.3. Product/Service Offerings
8.7.4. Strategies & recent developments
8.7.5. SWOT Analysis
8.8. Bio-Techne Corporation
8.8.1. Business Overview
8.8.2. Financial Performance
8.8.3. Product/Service Offerings
8.8.4. Strategies & recent developments
8.8.5. SWOT Analysis
8.9. EUROIMMUN AG
8.9.1. Business Overview
8.9.2. Financial Performance
8.9.3. Product/Service Offerings
8.9.4. Strategies & recent developments
8.9.5. SWOT Analysis
8.10. Quest Diagnostics
8.10.1. Business Overview
8.10.2. Financial Performance
8.10.3. Product/Service Offerings
8.10.4. Strategies & recent developments
8.10.5. SWOT Analysis
8.11. Trinity Biotech
8.11.1. Business Overview
8.11.2. Financial Performance
8.11.3. Product/Service Offerings
8.11.4. Strategies & recent developments
8.11.5. SWOT Analysis
8.12. Werfen
8.12.1. Business Overview
8.12.2. Financial Performance
8.12.3. Product/Service Offerings
8.12.4. Strategies & recent developments
8.12.5. SWOT Analysis
8.13. Hycor Biomedical
8.13.1. Business Overview
8.13.2. Financial Performance
8.13.3. Product/Service Offerings
8.13.4. Strategies & recent developments
8.13.5. SWOT Analysis
8.14. Oncimmune
8.14.1. Business Overview
8.14.2. Financial Performance
8.14.3. Product/Service Offerings
8.14.4. Strategies & recent developments
8.14.5. SWOT Analysis
8.15. Exagen Inc.
8.15.1. Business Overview
8.15.2. Financial Performance
8.15.3. Product/Service Offerings
8.15.4. Strategies & recent developments
8.15.5. SWOT Analysis

ページTOPに戻る

List of Tables/Graphs

Tables
TABLE 1.GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET VALUE, BY DISEASE TYPE, 2022-2028 (USD BILLION)
TABLE 2.GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET VALUE FOR ACTIVATED CARBON, BY GEOGRAPHY, 2022-2028 (USD BILLION)
TABLE 3.GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET VALUE FOR CARBON DERIVATIVES, BY GEOGRAPHY, 2022-2028 (USD BILLION)
TABLE 4.GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET VALUE FOR METAL OXIDES, BY GEOGRAPHY, 2022-2028 (USD BILLION)
TABLE 5.GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET VALUE FOR CONDUCTIVE POLYMERS, BY GEOGRAPHY, 2022-2028 (USD BILLION)
TABLE 6.GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2022-2028 (USD BILLION)
TABLE 7.GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET VALUE, BY END-USERS, 2022-2028 (USD BILLION)
TABLE 8.GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET VALUE FOR CONSUMER ELECTRONICS, 2022-2028 (USD BILLION)
TABLE 9.GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET VALUE FOR INDUSTRIAL, BY GEOGRAPHY, 2022-2028 (USD BILLION)
TABLE 10.GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET VALUE FOR TRANSPORTATION, BY GEOGRAPHY, 2022-2028 (USD BILLION)
TABLE 11.GLOBAL AUTOIMMUNE DISEASE DIAGNOSTICS MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2022-2028 (USD BILLION)
TABLE 12.NORTH AMERICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET VALUE, BY COUNTRY, 2022-2028 (USD BILLION)
TABLE 13.NORTH AMERICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET VALUE, BY DISEASE TYPE, 2022-2028 (USD BILLION)
TABLE 14.NORTH AMERICA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET VALUE, BY END-USERS, 2022-2028 (USD BILLION)
TABLE 15.U.S AUTOIMMUNE DISEASE DIAGNOSTICS MARKET VALUE, BY DISEASE TYPE, 2022-2028 (USD BILLION)
TABLE 16.U.S AUTOIMMUNE DISEASE DIAGNOSTICS MARKET VALUE, BY END-USERS, 2022-2028 (USD BILLION)
TABLE 17.CANADA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET VALUE, BY DISEASE TYPE, 2022-2028 (USD BILLION)
TABLE 18.CANADA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET VALUE, BY END-USERS, 2022-2028 (USD BILLION)
TABLE 19.EUROPE AUTOIMMUNE DISEASE DIAGNOSTICS MARKET VALUE, BY COUNTRY, 2022-2028 (USD BILLION)
TABLE 20.EUROPE AUTOIMMUNE DISEASE DIAGNOSTICS MARKET VALUE, BY DISEASE TYPE, 2022-2028 (USD BILLION)
TABLE 21.EUROPE AUTOIMMUNE DISEASE DIAGNOSTICS MARKET VALUE, END-USERS, 2022-2028 (USD BILLION)
TABLE 22.GERMANY AUTOIMMUNE DISEASE DIAGNOSTICS MARKET VALUE, BY DISEASE TYPE, 2022-2028 (USD BILLION)
TABLE 23.GERMANY AUTOIMMUNE DISEASE DIAGNOSTICS MARKET VALUE, BY END-USERS, 2022-2028 (USD BILLION)
TABLE 24.U.K AUTOIMMUNE DISEASE DIAGNOSTICS MARKET VALUE, BY DISEASE TYPE, 2022-2028 (USD BILLION)
TABLE 25.U.K AUTOIMMUNE DISEASE DIAGNOSTICS MARKET VALUE, BY END-USERS, 2022-2028 (USD BILLION)
TABLE 26.FRANCE AUTOIMMUNE DISEASE DIAGNOSTICS MARKET VALUE, BY DISEASE TYPE, 2022-2028 (USD BILLION)
TABLE 27.FRANCE AUTOIMMUNE DISEASE DIAGNOSTICS MARKET VALUE, BY END-USERS, 2022-2028 (USD BILLION)
TABLE 28.ITALY AUTOIMMUNE DISEASE DIAGNOSTICS MARKET VALUE, BY DISEASE TYPE, 2022-2028 (USD BILLION)
TABLE 29.ITALY AUTOIMMUNE DISEASE DIAGNOSTICS MARKET VALUE, BY END-USERS, 2022-2028 (USD BILLION)
TABLE 30.SPAIN SUPERCAPACITOR MATERIALS MARKET VALUE, BY DISEASE TYPE, 2022-2028 (USD BILLION)
TABLE 31.SPAIN SUPERCAPACITOR MATERIALS MARKET VALUE, BY END-USERS, 2022-2028 (USD BILLION)
TABLE 32.ROE AUTOIMMUNE DISEASE DIAGNOSTICS MARKET VALUE, BY DISEASE TYPE, 2022-2028 (USD BILLION)
TABLE 33.ROE AUTOIMMUNE DISEASE DIAGNOSTICS MARKET VALUE, BY END-USERS, 2022-2028 (USD BILLION)
TABLE 34.ASIA PACIFC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET VALUE, BY COUNTRY, 2022-2028 (USD BILLION)
TABLE 35.ASIA PACIFC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET VALUE, BY DISEASE TYPE, 2022-2028 (USD BILLION)
TABLE 36.ASIA PACIFC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET VALUE, BY END-USERS, 2022-2028 (USD BILLION)
TABLE 37.CHINA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET VALUE, BY DISEASE TYPE, 2022-2028 (USD BILLION)
TABLE 38.CHINA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET VALUE, BY END-USERS, 2022-2028 (USD BILLION)
TABLE 39.INDIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET VALUE, BY DISEASE TYPE, 2022-2028 (USD BILLION)
TABLE 40.INDIA AUTOIMMUNE DISEASE DIAGNOSTICS MARKET VALUE, BY END-USERS, 2022-2028 (USD BILLION)
TABLE 41.JAPAN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET VALUE, BY DISEASE TYPE, 2022-2028 (USD BILLION)
TABLE 42.JAPAN AUTOIMMUNE DISEASE DIAGNOSTICS MARKET VALUE, BY END-USERS, 2022-2028 (USD BILLION)
TABLE 43.REST OF APAC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET VALUE, BY DISEASE TYPE, 2022-2028 (USD BILLION)
TABLE 44.REST OF APAC AUTOIMMUNE DISEASE DIAGNOSTICS MARKET VALUE, BY END-USERS, 2022-2028 (USD BILLION)
TABLE 45.REST OF WORLD AUTOIMMUNE DISEASE DIAGNOSTICS MARKET VALUE, BY DISEASE TYPE, 2022-2028 (USD BILLION)
TABLE 46.REST OF WORLD AUTOIMMUNE DISEASE DIAGNOSTICS MARKET VALUE, BY END-USERS, 2022-2028 (USD BILLION)
TABLE 47.CABOT(NORIT): FINANCIALS
TABLE 48.CABOT(NORIT): PRODUCTS & SERVICES
TABLE 49.CABOT(NORIT): RECENT DEVELOPMENTS
TABLE 50.KURARY CO. LTD: FINANCIALS
TABLE 51.KURARY CO. LTD: PRODUCTS & SERVICES
TABLE 52.KURARY CO. LTD: RECENT DEVELOPMENTS
TABLE 53.BAYER MATERIALSCIENCE AG: FINANCIALS
TABLE 54.BAYER MATERIALSCIENCE AG: PRODUCTS & SERVICES
TABLE 55.BAYER MATERIALSCIENCE AG: RECENT DEVELOPMENTS
TABLE 56.CALGON CARBON CORPORATION: FINANCIALS
TABLE 57.CALGON CARBON CORPORATION: PRODUCTS & SERVICES
TABLE 58.CALGON CARBON CORPORATION: RECENT DEVELOPMENTS
TABLE 59.CARBON NT&F: FINANCIALS
TABLE 60.CARBON NT&F: PRODUCTS & SERVICES
TABLE 61.CARBON NT&F: RECENT DEVELOPMENTS
TABLE 62.SHENZHEN NTP: FINANCIALS
TABLE 63.SHENZHEN NTP: PRODUCTS & SERVICES
TABLE 64.SHENZHEN NTP: RECENT DEVELOPMENTS
TABLE 65.CECA SA: FINANCIALS
TABLE 66.CECA SA: PRODUCTS & SERVICES
TABLE 67.CECA SA: RECENT DEVELOPMENTS
TABLE 68.CNANO TECHNOLOGY: FINANCIALS
TABLE 69.CNANO TECHNOLOGY: PRODUCTS & SERVICES
TABLE 70.CNANO TECHNOLOGY: RECENT DEVELOPMENTS
TABLE 71.DONAU CHEMIE GROUP: FINANCIALS
TABLE 72.DONAU CHEMIE GROUP: PRODUCTS & SERVICES
TABLE 73.DONAU CHEMIE GROUP: RECENT DEVELOPMENTS
TABLE 74.SHOWA DENKO: FINANCIALS
TABLE 75.SHOWA DENKO: PRODUCTS & SERVICES
TABLE 76.SHOWA DENKO: RECENT DEVELOPMENTS